Brown Recluse Spider Bite Mediated Hemolysis: Clinical Features a Possible Role for Complement Inhibitor Therapy and Reduced RBC Surface Glycophorin A as a Potential Biomarker of Venom Exposure

摘要

BackgroundThe venom of Loxosceles reclusa (Brown Recluse spider) can cause a severe, life-threatening hemolysis in humans for which no therapy is currently available in the USA beyond supportive measures. Because this hemolysis is uncommon, relatively little is known about its clinical manifestation, diagnosis, or management. Here, we aimed to clarify the clinical details of envenomation, to determine the efficacy of the complement inhibitor eculizumab to prevent the hemolysis in vitro, and to investigate markers of exposure to Brown Recluse venom.